Middle East conflict cost escalations
Prolonged Middle East tensions may increase costs for sourcing, logistics, and working capital, with limited ability to pass through.
PIRAMALPHARMA / bear-case history
Track the concerns that keep returning.
Piramal Pharma · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Tariff impact on CDMO business
US tariffs on Indian pharma could affect innovation-related work; management noted multiple mitigation paths but uncertainty remains.
Intangible asset write-offs
A ₹176 crore impairment was taken on R&D intangibles due to changed market conditions; similar write-offs may recur.
Revenue lumpiness from CDMO
CDMO revenue remains H2-weighted, causing quarterly volatility; this pattern is expected to persist in FY27.